Checkpoint Therapeutics, Inc. Class Action
June 4th Lead Plaintiff Deadline Approaching in Class Action Against Checkpoint Therapeutics, Inc. – Contact Robbins LLP Today
May 21, 2024 20:05 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
Checkpoint Therapeutics, Inc. Class Action
Robbins LLP Reminds Stockholders of CKPT to Contact the Law Firm for Information About the Checkpoint Therapeutics, Inc. Class Action Lawsuit
April 26, 2024 16:56 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
Checkpoint Therapeutics, Inc. Class Action
CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action
April 15, 2024 17:14 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
Checkpoint Therapeutics, Inc. Class Action
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT)
April 07, 2024 23:21 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab